GlassScriptPhysician profile
Peter Demaria
NPI 1811230873
$1,181.20
in general payments reported to CMS, 2019-2025
23 companies · $936 in 2025
The $936 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $245 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $195.09 | 2025 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $155.22 | 2025 | Rezlidhia, Gavreto, Rezlidhia |
| E.R. Squibb & Sons, L.L.C. | $115.52 | 2025 | |
| Eko Health, INC. | $100.00 | 2024 | |
| Array Biopharma INC | $84.45 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Merck Sharp & Dohme LLC | $50.09 | 2024-2025 | Keytruda, Lynparza |
| Aveo Pharmaceuticals, INC. | $44.85 | 2025 | |
| Novartis Pharmaceuticals Corporation | $44.70 | 2024-2025 | |
| Pfizer INC. | $42.69 | 2024 | |
| Janssen Biotech, INC. | $42.39 | 2025 | Carvykti, Erleada |
| Sobi, INC | $38.83 | 2025 | |
| Amgen INC. | $30.87 | 2025 | Vectibix |
| Takeda Pharmaceuticals U.S.A., INC. | $27.86 | 2025 | Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $25.37 | 2024 | Enhertu |
| Stemline Therapeutics INC. | $24.75 | 2025 | Orserdu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $23.26 | 2025 | Zoladex |
| Invivyd INC | $23.12 | 2025 | Pemgarda |
| Taiho Oncology, INC. | $22.98 | 2025 | |
| Daiichi Sankyo INC. | $22.68 | 2025 | Vanflyta |
| Puma Biotechnology, INC. | $18.98 | 2025 | |
| Springworks Therapeutics, INC. | $18.54 | 2025 | Gomekli |
| Tolmar, INC. | $14.48 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $14.48 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Demaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.